AnGes, Inc.
- Biotech or pharma, therapeutic R&D
AnGes, Inc. is a commercial-stage biopharmaceutical company dedicated to developing innovative gene-based medicines built on cutting-edge technology platforms of gene therapy, DNA vaccine, nucleic acid and genome-editing. Its flagship gene therapy product Collategene®, a plasmid DNA encoding human HGF with breakthrough therapy designation, completed the US phase 2b clinical study to reveal effectiveness and safety in patients with chronic limb-threatening ischemia and non-healing ulcers. We are open to collaborate with partners on global development and commercialization of Collategene®.